Masakazu Toi

Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes

M. Piccart, Z. Aziz, D. Fraser, 2017, The Pharmacogenomics Journal.

Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial

K. Inoue, N. Masuda, S. Morita, 2018, Breast Cancer.

Clinical significance of plasma nucleosome levels in cancer patients.

M. Toi, K. Kuroi, C. Tanaka, 2001, International journal of oncology.

Circulating levels of endostatin in cancer patients.

M. Toi, K. Kuroi, C. Tanaka, 2001, Oncology reports.

Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari)

E. Tokunaga, M. Yamaguchi, N. Masuda, 2017, Breast Cancer Research and Treatment.

Clinical benefit of nomogram for predicting positive resection margins in breast conserving surgery.

W. Han, H. Moon, N. Cho, 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.